CSPC Innovation Pharmaceutical's subsidiary SYS6043, which is a holder of antibody drug conjugates, has obtained a notification letter for drug clinical trial approval.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA Jushibiopharm Co., Ltd. ("Jushibiopharm") recently received approval from the National Medical Products Administration for the clinical trial of SYS6043. The clinical trial will begin in the near future. SYS6043 is a monoclonal antibody-drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. SYS6043 is classified as a category 1 therapeutic biologic. The indication approved for this trial is advanced solid tumors, and it is expected to be used in the treatment of small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, prostate cancer, liver cell carcinoma, etc. Preclinical studies have shown that SYS6043 has good anti-tumor effects on various types of cancer, and it is expected to demonstrate good therapeutic effects in subsequent clinical trials. Multiple patent applications for this product have been submitted domestically and abroad.